Core Viewpoint - The mainstream joint venture automakers have shown a strong recovery in sales during the first half of the year, with notable growth in companies like FAW Toyota and SAIC Volkswagen, driven by the effectiveness of their "oil-electric integration" strategy [1][2]. Sales Performance - FAW Toyota sold 377,800 vehicles, a year-on-year increase of 16% - FAW-Volkswagen sold 436,100 vehicles, up 3.5% year-on-year - SAIC Volkswagen's sales reached 523,000 vehicles, a 2.3% increase - SAIC General sold 245,100 vehicles, marking an 8.64% growth - GAC Toyota achieved a total sales of 364,200 vehicles, showing positive growth [2]. Strategic Initiatives - The "oil-electric integration" strategy has helped stabilize the core market for fuel vehicles while accelerating the launch of competitive electric products [2][5]. - FAW-Volkswagen has implemented a three-step intelligent driving roadmap for fuel vehicles, aiming to enhance their competitiveness [3]. - GAC Toyota's flagship fuel vehicles, including Camry and Highlander, saw a total sales increase of 30% in the first half of the year [3]. Localization and R&D - Joint venture automakers are shifting their strategies from global technology import to local market dominance, with a focus on localized R&D [5][6]. - FAW Toyota's "RCE system" allows for localized decision-making and development, resulting in strong demand for the bZ5 electric model [5]. - Volkswagen aims to enhance its R&D capabilities in China, planning to launch over 11 new models by 2026 [6]. Marketing Strategies - The "one-price" marketing strategy has been widely adopted among joint venture automakers, enhancing sales through price transparency and significant discounts [8][9]. - This strategy simplifies the purchasing process and directly competes with new energy vehicle brands by offering substantial price reductions [9][10]. - The shift to a "one-price" model has improved consumer experience by eliminating uncertainties in pricing and enhancing service quality from dealers [10].

众会字（2025）第 08929 号 关于上海证券交易所 《关于闻泰科技股份有限公司 2024 年年度报告的信 息披露监管问询函》 有关财务问题回复的专项说明 关于上海证券交易所 《关于闻泰科技股份有限公司 2024 年年度报告的信息披露监管 问询函》有关财务问题回复的专项说明 上海证券交易所： 于 2024 年末，公司承担的有息负债及本年内相应承担的利息支出如下： 我们接受委托，审计了闻泰科技股份有限公司（以下简称"闻泰科技"或"公 司"）2024 年的年度财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债 表，2024 年度的合并及公司利润表、合并及公司现金流量表、合并及公司所有者 权益变动表以及财务报表附注，并出具了众会字（2025）第 04980 号审计报告。 贵所于 2025 年 5 月 23 日收到上海证券交易所《关于闻泰科技股份有限公司 师根据问询函的要求对问询函提出的相关问题进行了核查，回复如下： 问题一：年报及前期公告显示，2024 年末公司货币资金、交易性金融资产 账面余额分别为 78.34 亿元、17.63 亿元，合计金额 95.97 亿元，同比增长 存放于境外款项 2 ...

Meta Platforms(META.O)：在英国剑桥新建价值1600万美元的音频研究实验室。 ...

从行业市盈率排名来看，公司所处的生物制品行业市盈率平均74.16倍，行业中值44.75倍，神州细胞排 名第73位。 截至2025年一季报，共有13家机构持仓神州细胞，其中其他7家、基金6家，合计持股数33127.91万股， 持股市值134.96亿元。 7月9日，神州细胞今日收盘77.0元，下跌2.74%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到337.77倍，总市值342.91亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13神州细胞337.77306.30-84.73342.91亿行业平均 74.1659.3810.22203.06亿行业中值44.7540.852.9483.84亿1西藏药业11.7911.302.90118.84亿2长春高新 18.8516.031.76414.10亿3川宁生物20.1319.213.28268.95亿4安科生物20.9820.723.59146.51亿5英诺特 21.0416.712.0041.25亿6上海莱士22.9420.941.41459.35亿7派林生物23.7322.682.11169.08亿8华兰生物 25.3326.532 ...

作者：Hongyu 编辑：penny Listen Labs 由两位哈佛校友 Florian Juengermann 与 Alfred Wahlforss 在 2024 年底联合创立，并在 2025 年 4 月连获 Sequoia 领投的种子轮与 A 轮合计 2700 万美元融资，目标是打造一套能 自动招募受访者、主持上千场多语访谈、即时归档并复用洞察 的"AI 用户研究员"体系。 今年 2–5 月，Listen Labs 依次发布三项核心能力：1） AI Interviewer 可同时主持上千场语音/视频深访并动态追问；2） Insight Engine 把转录、情绪与行为 数据送入 GPT-4o 管线，几分钟生成主题聚类与可下载 PPT；3） Research Warehouse 将所有历史项目向量化存档，研究者可像 ChatGPT 一样对话检索并触 发"一键再访谈"。 在 AI 赋能用户研究的两条主线中，一条是传统无主持可用性测试借助 LLM 做摘要与打标签；另一条则是 Listen Labs 所聚焦的 全流程自动化深访 ——让 AI 主持人+ 用户访谈池（panel network）把"招募-访谈-分 ...

Group 1: Core Activities and Offerings - Beijing's cultural and tourism bureau has launched the "Jingcai Summer" series of activities, featuring over 150 summer-themed events, 6,200 premium performances, and 3,800 cultural experience activities [1] - The "Graduation Season in Beijing" initiative includes 10 recommended activities for graduates, with various scenic spots offering free admission and special discounts for high school and college graduates [3] - A total of 10 thematic study tours will be introduced, focusing on red history, traditional arts, and natural exploration, aimed at both domestic and international students [4] Group 2: Performance and Entertainment - The summer performance market will feature 45 youth-oriented shows, 12 art summer camps, and various international performances, including classic plays and children's theater [5] - Notable performances include the comedy "Twelfth Night" and the drama "The Seagull," along with international productions such as Russian plays and Italian musicals [5] Group 3: Tourism and Leisure Activities - The "Summer Rural Tourism Plan" includes seven rural tourism routes, promoting natural exploration and water activities, with free tickets and discounts offered at various scenic spots [6] - Nighttime activities such as night markets, outdoor movies, and music festivals are being organized across different districts to enhance summer leisure experiences [7][8] Group 4: Visitor Experience and Services - The city is focusing on improving visitor experiences by extending opening hours at certain attractions and implementing convenient entry measures for tourists [8] - The "Fly Summer" theme at the Capital Airport includes promotional activities offering discounts on duty-free, dining, and retail [8] Group 5: Safety and Engagement - Tourists are advised to take precautions against heat and ensure safety while traveling, with a call for adherence to public order and tourism etiquette [9] - The tourism bureau encourages visitors to share their experiences on social media platforms, promoting engagement with the "JingcaiSummer" and "BeijingStyle" hashtags [9]

Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has initiated a Phase III clinical trial for its self-developed drug, Rumaine (generic name: Luwomeitini tablets), aimed at treating pediatric low-grade glioma in mainland China [1][2]. Drug Information and Research Status - Rumaine is an innovative small molecule chemical drug that acts as a selective inhibitor of MEK1/2 [1]. - As of July 9, 2025, the drug is in Phase III clinical trials for treating pediatric low-grade glioma and is also in Phase II trials for treating extra-cranial arteriovenous malformations and pediatric Langerhans cell histiocytosis in mainland China [2]. - The drug has been included in the breakthrough therapy program by the National Medical Products Administration for two indications: inoperable or residual/recurrent NF1-related plexiform neurofibromas in adult patients and pediatric Langerhans cell histiocytosis [2]. - Cumulative R&D investment in the drug reached approximately RMB 607 million (unaudited) as of May 2025 [2]. - According to IQVIA MIDAS™, global sales of MEK1/2 selective inhibitors are projected to be approximately USD 2.068 billion in 2024 [2].

科前生物公告，公司拟与华中农大签订专利实施许可合同、研发及技术许可合同。公司就两个研发项目 一共需向华中农大支付335万元人民币。其中，"一株猪δ冠状病毒强毒株及其在疫苗制备中的应用"发明 专利的实施许可支付135万元，"吉氏巴贝斯虫传代致弱活疫苗"的研发及技术许可支付200万元。 ...

复星医药：控股子公司药品芦沃美替尼片中国境内启动Ⅲ期临床试验 智通财经7月9日电，复星医药(600196.SH)公告称，控股子公司上海复星医药产业发展有限公司就复迈 宁®（通用名：芦沃美替尼片）用于治疗儿童低级别脑胶质瘤于中国境内启动Ⅲ期临床试验。该药品为 集团自主研发的创新型小分子化学药物，为MEK1/2选择性抑制剂，已在中国境内上市并获批两项适应 症。截至2025年5月，集团针对该药品的累计研发投入约为人民币6.07亿元。根据IQVIA数据，2024 年，MEK1/2选择性抑制剂于全球范围的销售额约为20.68亿美元。药品研发存在一定风险，敬请广大投 资者注意投资风险。 ...

证券代码：002923 证券简称：润都股份 珠海润都制药股份有限公司 答：公司始终秉持"规范、专业、发展"的理念，以专注铸就卓越，以技 术引领未来。积极推动绿色化和合成生物技术的应用，加速仿制药与创新 药的研发与上市。公司将顺应医药行业发展趋势，重点围绕心脑血管、消 化系统、解热镇痛、手术麻醉用药等领域，做优做强制剂产业，持续保持 独具特色的药物新剂型和肠溶、 缓控释制剂技术优势，加快高技术壁垒 仿制药和原创新药研发上市，拓展全渠道终端，打造立体品牌。 6、原料药沙坦类价格趋势？ 答：随着公司全球化销售网络的稳步推进，大客户项目持续转化落地，沙 坦类产品销量不断攀升，进一步夯实了公司沙坦类产品的市场竞争力；受 供需关系等多重因素影响，沙坦类产品市场竞争依然激烈，市场销售价格 仍在低位区间波动。 | 关于本次活动 是否涉及应披 | | | --- | --- | | | 无 | | 露重大信息的 | | | 说明 | | | 附件清单 | 无 | | （如有） | | | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻 ...